Table 2. Risk factors of modification of an antiretroviral regimen containing raltegravir versus dolutegravir within the first year of treatment because of toxicity or intolerance.

	Univariate analysis			Multivariate analysis
Variable	HR	95% CI	P value	HRa	95% CI	P value
Female	1.86	1.39–2.49	<0.001	1.98	1.45–2.71	<0.001
Age, per 10 years older	0.91	0.80–1.04	0.156	0.93	0.81–1.07	0.319
Nonwhite ethnicity	1.00	0.69–1.46	0.986	0.75	0.50–1.13	0.172
Prior AIDS-defining condition	0.86	0.61–1.22	0.405	0.89	0.56–1.41	0.513
HCV-coinfection	0.90	0.64–1.26	0.538	0.80	0.56–1.14	0.221
CD4+ cells per μl
<350		Reference			Reference
350–500	0.89	0.58–1.35	0.573	0.98	0.63–1.49	0.880
>500	0.98	0.70–1.39	0.922	1.07	0.73–1.56	0.735
HIV RNA >100 000 copies per ml	1.45	0.87–2.42	0.157	1.53	0.86–2.71	0.149
Treatment naive	1.07	0.70–1.64	0.739	1.05	0.64–1.70	0.858
Backbone
Abacavir–lamivudine		Reference			Reference
Tenofovir–emtricitabine	1.05	0.75–1.47	0.773	0.91	0.63–1.32	0.626
Other	1.07	0.74–1.55	0.701	0.97	0.64–1.49	0.902
Raltegravir versus dolutegravir	1.27	0.95–1.70	0.106	1.30	0.92–1.84	0.140

Hazard ratios in univariate and multivariate analysis.

CI, confidence interval; HR, hazard ratio.

^aadjusted for all variables listed.